Publications

The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death.

Author(s): Marcus PM,  Gareen IF,  Miller AB,  Rosenbaum J,  Keating K,  Aberle DR,  Berg CD

Journal: Contemp Clin Trials

Date: 2011 Nov

Major Program(s) or Research Group(s): BRG

PubMed ID: 21782037

PMC ID: PMC3185147

Abstract: BACKGROUND: Randomized controlled trials (RCTs) evaluating cancer screening modalities usually employ cause-specific mortality as their primary endpoint. Because death certificate cause of death can be inaccurate, RCTs frequently use review committees to assign an underlying cause of death. We describe the National Lung Screening Trial's (NLST's) death review approach, the Endpoint Verification Process (EVP), which strives to minimize errors in assignment of cause of death due to lung cancer. METHODS: Deaths selected for review include those with a notation of lung cancer on the death certificate and those occurring among participants ever diagnosed with lung cancer. Other criteria that trigger death review include, but are not limited to, death within 6 months of a screen suspicious for lung cancer and death within 60 days of certain diagnostic evaluation procedures associated with a screen suspicious for lung cancer or a lung cancer diagnosis. EVP requires concordance on whether death was due to lung cancer. Deaths are first reviewed by the EVP chair. If concordance is not achieved, the death is next reviewed by an Endpoint Verification Team (EVT) member. If concordance between the chair- and member-assigned cause of death is not achieved, the death is next reviewed by a group of at least three EVT members. Cause of death is assigned at the step in which concordance was achieved, or if necessary, at the team review. CONCLUSIONS: NLST's EVP is designed to produce a highly accurate count of lung cancer deaths.